Leadership Transition - Marc Forth is stepping down as President and CEO of AEON Biopharma, effective April 4, 2025, to pursue another opportunity, but will remain on the Board of Directors [1] - Jost Fischer, the current Chairman of the Board, will serve as Interim CEO while the Board searches for a permanent replacement [1][2] Company Progress and Strategy - AEON is making progress along a 351(k) biosimilar regulatory pathway to potentially bring ABP-450 to the U.S. market for all of BOTOX's approved and future therapeutic indications under a single FDA approval [2] - The company anticipates a Biosimilar BPD Type 2a meeting with the FDA in the second half of 2025, with current cash balance expected to support this process [2] Product Development - AEON is focused on developing its proprietary botulinum toxin complex, ABP-450, for debilitating medical conditions, initially targeting the neurosciences market [3] - ABP-450 is the same botulinum toxin complex marketed for cosmetic use as Jeuveau by Evolus and is approved as a biosimilar in Mexico and India [3]
AEON Biopharma Announces CEO Transition